ClinicalTrials.gg
CompletedNCT05761587VPOMIONCOLUpdated Nov 17, 2026

Validation of a Screening Scale for Misuse of Opioid Analgesics

An observational study in Cancer, Pain and Opioid Analgesic Adverse Reaction, sponsored by University Hospital, Clermont-Ferrand. Completed at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by University Hospital, Clermont-Ferrand · Observational

How we know

Updated Nov 17, 2026Now CompletedResults publication added+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
138
Ages
18 Years and older
Sex
All
01

Study summary

In oncology, pain is one of the main symptoms of discomfort. It has a significant impact on the quality of life.The use of opioid analgesics is recommended for the treatment of moderate to severe cancer pain.The misuse of opioid analgesics is an international public health problem.Different scales have been developed to help the prescriber screen for the risk of misuse in the general population. Patients with cancer-related pain are also at risk for aberrant opioid-related behaviors, misuse or addiction.

The main objectif of this study is to validate of the screening scale for the misuse of opioid analgesics in patients with chronic pain related to cancer. (Prescription Opioid Misuse Index - POMI).

Read the detailed description

The study takes place in 2 phases.

Test phase :

Questionnaire no. 1 constitutes the data for the TEST phase: it includes socio-demographic data, medical and family history, lifestyle, treatments, 5 questions from the Concise Pain Questionnaire (QCD), the French version of the POMI scale, the diagnostic criteria of the DSM-V and two questions concerning anxiety associated with pain and therapeutic education.

Retest phase :

questionnaire no. 2 10 to 15 days later.

02

Conditions studied

  • Cancer
  • Pain
  • Opioid Analgesic Adverse Reaction
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 138 is below the median of 200 across 2,644 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

University Hospital, Clermont-Ferrand is the lead sponsor of 859 studies on the registry; 177 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Cancer patients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 and over,
  • Patients with chronic cancer-related pain that has been evolving for at least 3 months,
  • Patients with a regular prescription of at least one opioid analgesic medicine taken daily for at least 1 month,
  • Patients followed in oncology for an active cancerous pathology.

Exclusion criteria

Exclusion Criteria:

  • Stopping opioid prescriptions on the day of the test phase (no Retest possible),
  • Patients in the process of weaning (risk of being weaned during the Retest phase),
  • Patients unable to complete the questionnaire on their own,
  • Patients followed in a pain or addiction centre,
  • Patients in terminal palliative situations of their cancer,
  • Patients with chronic pain that is more disabling than cancer-related pain,
  • Patients refusing to participate,
  • Patients under guardianship or curatorship,
  • Pregnant or breastfeeding patients,
  • Patient with a language barrier limiting understanding of the questionnaire in French.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
138 participants (actual)
Patient registry
No

Groups and cohorts

  • cancer patients

    Questionnaires

    Other: Questionnaires

Interventions

  • OtherQuestionnaires

    questionnaire including socio-demographic data, medical and family history, lifestyle, treatments, 5 questions from the Questionnaire Concis sur les Douleurs (QCD), the French version of the POMI scale, the diagnostic criteria of the DSM-V and two questions concerning anxiety associated with pain and therapeutic education.

06

What researchers measure

Primary outcomes

  1. POMI scale score - Prescription Opioid Misuse Index

    8-item self-assessment scale

    Time frame: day 1

  2. POMI scale score - Prescription Opioid Misuse Index

    8-item self-assessment scale

    Time frame: day 15

Secondary outcomes

  1. QCD

    Visual Analogue Scales (VAS) for assessing the intensity and daily impact of pain (0-10)

    Time frame: day 1

  2. QCD

    Visual Analogue Scales (VAS) for assessing the intensity and daily impact of pain (0-10)

    Time frame: day 15

  3. Sociodemographic characteristics

    Questionnaire about Sociodemographic characteristics of patients

    Time frame: day 1

  4. Lifestyle habits, other consumption

    Questionnaire about Lifestyle habits, other consumption

    Time frame: day 1

  5. Analgesic treatments

    Questionnaire about Ongoing analgesic treatments

    Time frame: day 1

  6. Use of analgesics

    Question evaluating the use of analgesics in the context of anticipating pain

    Time frame: day 1

  7. Use of analgesics

    Question evaluating the use of analgesics in the context of anticipating pain

    Time frame: day 15

07

Study locations

2 sites
  • CHU de Clermont-Ferrand
    Clermont-Ferrand, France
  • CH Le Puy en Velay
    Le Puy-en-Velay, 43000, France
08

References and documents

Publications

  • Guastella V, Bianchi M, Hanniet E, Pereira B, Authier N. Identifying opioid misuse in cancer pain: validation of the prescription opioid misuse index in a multicenter study. Support Care Cancer. 2025 Oct 4;33(10):902. doi: 10.1007/s00520-025-09942-4. PubMed 41044384 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Dec 2024, 22 months.

Of 1,099 non-industry observational studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 227. This study's 22 months is below that.

Counting every sponsor, half of 1,247 studies reached it within 58 months; a quarter within 24 and three quarters within 210.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Apr 2024 → Dec 2024 and completion Apr 2025 → Jun 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2023
First posted
Mar 9, 2023
StartActual
Feb 23, 2023
Primary completionActual
Dec 30, 2024was Apr 2024
CompletionActual
Jun 30, 2025was Apr 2025
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Nov 17, 2026
Primary completion
Apr 1, 2024→Dec 30, 2024 (actual)
Nov 17, 2026
Study completion
Apr 1, 2025→Jun 30, 2025 (actual)
Nov 17, 2026
Enrollment
150 (estimated)→138 (actual)
Nov 17, 2026
Publications
Results publication added: Guastella V, Bianchi M, Hanniet E, Pereira B, Authier N. Identifying opioid misuse in cancer pain: validation of the prescription opioid misuse index in a mult… PubMed 41044384 ↗
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Status unknown→Completed
    Publications Results publication added: Guastella V, Bianchi M, Hanniet E, Pereira B, Authier N. Identifying opioid misuse in cancer pain: validation of the prescription opioid misuse index in a mult… PubMed 41044384 ↗
    Primary completion Apr 1, 2024→Dec 30, 2024 (now actual)
    Study completion Apr 1, 2025→Jun 30, 2025 (now actual)
    Enrollment 150 (estimated)→138 (actual)
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05761587
Responsible party
Sponsor
First posted
Mar 9, 2023
Start date
Feb 23, 2023
Primary completion
Dec 30, 2024
Completion
Jun 30, 2025
Last update
Nov 17, 2026

Study contacts

Virginie Guastella
principal investigator · University Hospital, Clermont-Ferrand

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion